WO2009025239A1 - 新規外用剤 - Google Patents

新規外用剤 Download PDF

Info

Publication number
WO2009025239A1
WO2009025239A1 PCT/JP2008/064621 JP2008064621W WO2009025239A1 WO 2009025239 A1 WO2009025239 A1 WO 2009025239A1 JP 2008064621 W JP2008064621 W JP 2008064621W WO 2009025239 A1 WO2009025239 A1 WO 2009025239A1
Authority
WO
WIPO (PCT)
Prior art keywords
external use
compound
preparation
hydrate
salt
Prior art date
Application number
PCT/JP2008/064621
Other languages
English (en)
French (fr)
Inventor
Chiharu Kimura
Maho Sakurai
Original Assignee
Eisai R & D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R & D Management Co., Ltd. filed Critical Eisai R & D Management Co., Ltd.
Priority to AU2008290001A priority Critical patent/AU2008290001B2/en
Priority to AT08827867T priority patent/ATE549320T1/de
Priority to JP2009529019A priority patent/JP5060561B2/ja
Priority to EP08827867A priority patent/EP2202229B1/en
Priority to US12/673,715 priority patent/US8513269B2/en
Priority to CA2696793A priority patent/CA2696793A1/en
Priority to CN2008800220038A priority patent/CN101687819B/zh
Publication of WO2009025239A1 publication Critical patent/WO2009025239A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

　一般式（Ｉ）で表される化合物もしくはその塩またはそれらの水和物は、優れた止痒効果を奏し、かつ代謝面でも優れた効果を奏する。本発明の外用剤は、一般式（Ｉ）で表される化合物もしくはその塩またはそれらの水和物の皮膚への吸収性に優れている。また、本発明の外用剤は、長期間保存しても配合成分が分離し難いため安定性に優れている。 ［式中、Ｒは水酸基、Ｃ１－６アルコキシ基で置換されてもよいＣ１－６アルコキシ基、またはＣ１－６アルキル基で置換されてもよいアミノ基を示す。］
PCT/JP2008/064621 2007-08-17 2008-08-15 新規外用剤 WO2009025239A1 (ja)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2008290001A AU2008290001B2 (en) 2007-08-17 2008-08-15 Novel preparation for external use
AT08827867T ATE549320T1 (de) 2007-08-17 2008-08-15 Neue zubereitung für die äusserliche anwendung
JP2009529019A JP5060561B2 (ja) 2007-08-17 2008-08-15 新規外用剤
EP08827867A EP2202229B1 (en) 2007-08-17 2008-08-15 Novel preparation for external use
US12/673,715 US8513269B2 (en) 2007-08-17 2008-08-15 Preparation for external use
CA2696793A CA2696793A1 (en) 2007-08-17 2008-08-15 Novel preparation for external use
CN2008800220038A CN101687819B (zh) 2007-08-17 2008-08-15 外用剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-212926 2007-08-17
JP2007212926 2007-08-17

Publications (1)

Publication Number Publication Date
WO2009025239A1 true WO2009025239A1 (ja) 2009-02-26

Family

ID=40378144

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/064621 WO2009025239A1 (ja) 2007-08-17 2008-08-15 新規外用剤

Country Status (10)

Country Link
US (1) US8513269B2 (ja)
EP (1) EP2202229B1 (ja)
JP (1) JP5060561B2 (ja)
KR (1) KR20100042246A (ja)
CN (1) CN101687819B (ja)
AT (1) ATE549320T1 (ja)
AU (1) AU2008290001B2 (ja)
CA (1) CA2696793A1 (ja)
TW (1) TWI414296B (ja)
WO (1) WO2009025239A1 (ja)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013054809A1 (ja) * 2011-10-14 2013-04-18 大正製薬株式会社 皮膚外用剤
JP2013147442A (ja) * 2012-01-18 2013-08-01 Kose Corp グリチルレチン酸ステアリルの皮膚浸透促進剤
JP2014525425A (ja) * 2011-08-31 2014-09-29 アマケン エンヴェー 新規のｒｏｃｋキナーゼ阻害剤
JPWO2014133020A1 (ja) * 2013-02-28 2017-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 呼吸器疾患の予防治療剤
JP2019519543A (ja) * 2016-06-07 2019-07-11 デルマヴァント サイエンシーズ ゲーエムベーハーＤｅｒｍａｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ Ｐｄｅ−４阻害剤の局所処方物およびそれらの使用方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123641A4 (en) 2007-02-16 2011-06-22 Eisai R&D Man Co Ltd CRYSTAL, AMORPHOUS FORM AND METHYL N-Ý3- (6,7-DIMETHOXY-2-METHYLAMINOQUINAZOLINE-4-YL) PHENYLENE TEREPHTALIC ACID SALT
ATE538102T1 (de) 2007-08-17 2012-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung eines chinazolinderivats
CN110913862B (zh) * 2017-11-20 2022-12-30 江苏恒瑞医药股份有限公司 一种局部给药的药物组合物及其制备方法
CA3083786A1 (en) * 2017-12-07 2019-06-13 Dermavant Sciences GmbH Topical ointment formulations of pde-4 inhibitor and their use in treating skin conditions
WO2019113475A1 (en) * 2017-12-07 2019-06-13 Dermavant Sciences GmbH Topical ointment formulations and their use in treating skin conditions
MX2021001209A (es) * 2018-08-16 2021-04-12 Dr Reddy´S Laboratories Ltd Composiciones oleaginosas topicas.
WO2021262956A1 (en) * 2020-06-24 2021-12-30 Roivant Sciences Gmbh Topical gel formulations and their use in treating skin conditions

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517481A (ja) 1990-09-04 1993-01-26 Fujisawa Pharmaceut Co Ltd 軟膏剤
JPH08165251A (ja) 1994-12-12 1996-06-25 Hisamitsu Pharmaceut Co Inc 溶解剤および該溶解剤を含有する外用製剤
WO1999037622A1 (fr) 1998-01-26 1999-07-29 Eisai Co., Ltd. Derives heterocycliques azotes et medicaments produits a partir de ces derives
JP2001192385A (ja) 1999-10-25 2001-07-17 Yamanouchi Pharmaceut Co Ltd ナフチリジン誘導体
JP2005029541A (ja) 2003-07-11 2005-02-03 Shiseido Co Ltd 油中水型皮膚外用医薬品製剤
JP2005047909A (ja) 2003-07-17 2005-02-24 Santen Pharmaceut Co Ltd ピペリジン誘導体を有効成分とする掻痒治療剤
JP2005529930A (ja) 2002-05-28 2005-10-06 アルタナ　ファルマ　アクチエンゲゼルシャフト 局所適用可能な薬剤学的製剤
JP2005537262A (ja) 2002-07-11 2005-12-08 エルビオン アクチエンゲゼルシャフト 皮膚疾患の局所的治療
WO2007097317A1 (ja) 2006-02-21 2007-08-30 Eisai R & D Management Co., Ltd. ４－（３－ベンゾイルアミノフェニル）－６，７－ジメトキシ－２－メチルアミノキナゾリン誘導体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
AR029185A1 (es) 1999-10-25 2003-06-18 Yamanouchi Pharma Co Ltd Derivado de naftiridina
US20060258703A1 (en) 2003-07-17 2006-11-16 Ono Pharmaceutical Co., Ltd. Remedy for pruritus comprising piperidine derivative as the active ingredient
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2008137892A (ja) 2005-03-04 2008-06-19 Eisai Co Ltd 止痒剤
TWI404709B (zh) 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
EP2123641A4 (en) 2007-02-16 2011-06-22 Eisai R&D Man Co Ltd CRYSTAL, AMORPHOUS FORM AND METHYL N-Ý3- (6,7-DIMETHOXY-2-METHYLAMINOQUINAZOLINE-4-YL) PHENYLENE TEREPHTALIC ACID SALT

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517481A (ja) 1990-09-04 1993-01-26 Fujisawa Pharmaceut Co Ltd 軟膏剤
JPH08165251A (ja) 1994-12-12 1996-06-25 Hisamitsu Pharmaceut Co Inc 溶解剤および該溶解剤を含有する外用製剤
WO1999037622A1 (fr) 1998-01-26 1999-07-29 Eisai Co., Ltd. Derives heterocycliques azotes et medicaments produits a partir de ces derives
US6352989B1 (en) 1998-01-26 2002-03-05 Eisai Co., Ltd. Nitrogenous heterocyclic derivatives and medicine thereof
JP2001192385A (ja) 1999-10-25 2001-07-17 Yamanouchi Pharmaceut Co Ltd ナフチリジン誘導体
JP2005529930A (ja) 2002-05-28 2005-10-06 アルタナ　ファルマ　アクチエンゲゼルシャフト 局所適用可能な薬剤学的製剤
JP2005537262A (ja) 2002-07-11 2005-12-08 エルビオン アクチエンゲゼルシャフト 皮膚疾患の局所的治療
JP2005029541A (ja) 2003-07-11 2005-02-03 Shiseido Co Ltd 油中水型皮膚外用医薬品製剤
JP2005047909A (ja) 2003-07-17 2005-02-24 Santen Pharmaceut Co Ltd ピペリジン誘導体を有効成分とする掻痒治療剤
WO2007097317A1 (ja) 2006-02-21 2007-08-30 Eisai R & D Management Co., Ltd. ４－（３－ベンゾイルアミノフェニル）－６，７－ジメトキシ－２－メチルアミノキナゾリン誘導体
US20070299094A1 (en) 2006-02-21 2007-12-27 Eisai R&D Management Co., Ltd. 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAPAN PHARMACEUTICAL EXCIPIENTS COUNCIL: "Iyakuhin tenkabutsu jiten 2007", 25 July 2007, YAKUJI NIPPO LTD., pages: 280 - 282,309 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525425A (ja) * 2011-08-31 2014-09-29 アマケン エンヴェー 新規のｒｏｃｋキナーゼ阻害剤
WO2013054809A1 (ja) * 2011-10-14 2013-04-18 大正製薬株式会社 皮膚外用剤
JPWO2013054809A1 (ja) * 2011-10-14 2015-03-30 大正製薬株式会社 皮膚外用剤
JP2013147442A (ja) * 2012-01-18 2013-08-01 Kose Corp グリチルレチン酸ステアリルの皮膚浸透促進剤
JPWO2014133020A1 (ja) * 2013-02-28 2017-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 呼吸器疾患の予防治療剤
JP2019519543A (ja) * 2016-06-07 2019-07-11 デルマヴァント サイエンシーズ ゲーエムベーハーＤｅｒｍａｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ Ｐｄｅ−４阻害剤の局所処方物およびそれらの使用方法

Also Published As

Publication number Publication date
AU2008290001A1 (en) 2009-02-26
TW200922589A (en) 2009-06-01
KR20100042246A (ko) 2010-04-23
EP2202229A1 (en) 2010-06-30
EP2202229A4 (en) 2010-09-08
JP5060561B2 (ja) 2012-10-31
CN101687819A (zh) 2010-03-31
CN101687819B (zh) 2013-03-20
US20110021545A1 (en) 2011-01-27
CA2696793A1 (en) 2009-02-26
JPWO2009025239A1 (ja) 2010-11-25
US8513269B2 (en) 2013-08-20
AU2008290001B2 (en) 2012-08-09
EP2202229B1 (en) 2012-03-14
TWI414296B (zh) 2013-11-11
ATE549320T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
WO2009025239A1 (ja) 新規外用剤
MX2010004493A (es) Compuestos de tropano.
MY162940A (en) Quinoline derivative-containing pharmaceutical composition
NZ601489A (en) Cyclic amine compound and acaricide
WO2008101682A3 (en) Iminipyridine derivatives and their uses as microbiocides
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
WO2013085554A3 (en) Oxidative dyeing compositions comprising an 1-hexyl/heptyl-4,5-diaminopyrazole and a naphthalen-1-ol and derivatives thereof
WO2010003133A3 (en) Cdk modulators
WO2009028629A1 (ja) 複素環化合物およびその用途
WO2009117150A3 (en) Method of treating lupus with ceramide derivatives
WO2009024342A3 (en) Novel microbiocides
WO2008025965A3 (en) Retinoid compounds and their use
MY158158A (en) Solid preparation
WO2009153461A3 (fr) Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro-2h-3- benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
WO2011001113A3 (fr) NOUVEAUX DERIVES DE 1,2,3,4-TETRAHYDRO-PYRIMIDO{1,2-a}PYRIMIDIN-6-ONE,LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE
WO2007058568A3 (fr) Sels et melanges d'acide 9-oxoacridine-10-acetique et de 1-alkylamino-1-desoxypolyols, compositions pharmaceutiques les contenant, et methodes de traitement associees
NZ587490A (en) Anti-Microbial Compounds containing compounds with a sugar substituent
WO2010013835A3 (en) Solid pharmaceutical composition
WO2008126652A1 (ja) 皮膚外用組成物
WO2008113450A3 (de) Verwendung von chroman-4-on-derivaten
RS51068B (sr) Derivati-5-piridinil-1-azabiciklo[3.2.1]oktana, njihovo dobijanje i njihova terapeutska primena
WO2009011988A3 (en) Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
JO2726B1 (en) Derivatives 4- (3-benzoylaminophenyl) -6,7-dimethoxy-2-methylaminokinazoline
EP1797757A4 (en) WELL STORED DICHLORISOCYANOIC ACID SALT COMPOSITION
WO2010067010A3 (fr) Derives de morphine-6-glucuronide, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880022003.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08827867

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009529019

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20097026236

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2696793

Country of ref document: CA

Ref document number: 204018

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008827867

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008290001

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1457/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12673715

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2008290001

Country of ref document: AU

Date of ref document: 20080815

Kind code of ref document: A